期刊文献+

地西他滨联合减量预激化疗方案治疗高龄急性髓系白血病二例并文献复习 被引量:4

Decitabine combined with reduced pre-excitation chemotherapy for elderly acute myeloid leukemia: report of two cases and review of literature
原文传递
导出
摘要 目的分析地西他滨联合减量预激化疗方案治疗高龄急性髓系白血病(AML)患者的疗效及安全性。方法采用3 d地西他滨联合减量预激化疗方案治疗2例高龄AML患者,观察其疗效、不良反应,并复习相关文献。结果2例高龄AML患者耐受性良好,经1个疗程治疗后获得完全缓解,血象明显改善,但化疗后均出现3~4级骨髓抑制,并发肺炎和诱发心功能受损。其中1例高龄患者同时合并上消化道出血,经积极处理后得到有效控制。结论高龄并不是AML患者化疗的绝对禁忌,地西他滨联合减量预激化疗方案针对高龄AML患者疗效确切,可以作为高龄AML患者的治疗新选择,但感染及继发脏器功能受损仍是其主要的不良反应,需及时处理并加强支持治疗。
作者 李章坤 赖应昌 钟玉钗 姚灼新 姚淑仪 何继祥 Li Zhangkun;Lai Yingchang;Zhong Yuchai;Yao Zhuoxin;Yao Shuyi;He Jixiang(Department of Hematology,Dongguan People" s Hospital,Dongguan 523059,Chin;Clinical Laboratory,Dongguan People" s Hospital,Dongguan 523059,China)
出处 《白血病.淋巴瘤》 CAS 2018年第9期554-556,共3页 Journal of Leukemia & Lymphoma
基金 东莞市社会科技发展项目(201750715001297)
  • 相关文献

参考文献3

二级参考文献27

  • 1Farag SS,Archer KJ,Mrózek K,et al.Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia:results from Cancer and Leukemia Group B 8461[J].Blood,2006,108:63-73. 被引量:1
  • 2Ghanem H,Cornelison AM,Garcia-Manero G,et al.Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome[J].Clin Lymphoma Myeloma Leuk,2013,13 Suppl 2:S289-294. 被引量:1
  • 3Cashen AF,Schiller GJ,O'Donnell MR,et al.Multicenter,phase Ⅱ study of decitabine for the first-line treatment of older patients with acute myeloid leukemia[J].J Clin Oncol,2010,28:556-561. 被引量:1
  • 4Appelbaum FR,Gundacker H,Head DR,et al.Age and acute myeloid leukemia[J].Blood,2006,107:3481-3485. 被引量:1
  • 5Burnett AK,Milligan D,Prentice AG,et al.A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment[J].Cancer,2007,109:1114-1124. 被引量:1
  • 6Issa JP,Gharibyan V,Cortes J,et al.Phase 1Ⅱ study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate[J].J Clin Oncol,2005,23:3948-3956. 被引量:1
  • 7Ryningen A,Stapnes C,Bruserud.Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting[J].Leuk Res,2007,31:1303-1313. 被引量:1
  • 8Ng KP,Ebrahem Q,Negrotto S,et al.p53 independent epigeneticdifferentiation treatment in xenotransplant models of acute myeloid leukemia[J].Leukemia,2011,25:1739-1750. 被引量:1
  • 9Qin T,Youssd EM,Jelinek J,et al.Effect of cytarabine and decitabine in combination in human leukemic cell lines[J].Clin Cancer Res,2007,13:4225-4232. 被引量:1
  • 10Curran MP.Decitabine:a review of its use in older patients with acute myeloid leukaemia[J].Drugs Aging,2013,30:447-458. 被引量:1

共引文献18

同被引文献46

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部